Chapter 2 Pathobiology of Novel Approaches to Treatment

Publication date: 2018
Source:Interstitial Lung Disease
Author(s): Silvia Puglisi, Carlo Vancheri
Comprehension of the pathobiology of any disease is crucial to identifying the cellular and molecular mechanisms through which that disease arises and evolves. This may lead to the discovery of new drugs that, acting on specific targets, may be effective in slowing or stopping the disease. Idiopathic pulmonary fibrosis (IPF) is a complex disease involving exogenous risk factors, genetic predisposition, and aging. Nevertheless, substantial information about the cellular and molecular pathways involved in IPF is, at least in part, clear. By virtue of this, two different drugs—pirfenidone and nintedanib—have been developed and approved for the treatment of IPF, and a number of preclinical and clinical studies are currently under way exploring new potential drugs.



http://ift.tt/2qaQD36